Skip to main content
Premium Trial:

Request an Annual Quote

Human Genome Sciences Posts Widened Loss Amid Shriveled Revenue

NEW YORK, Feb. 14 - Human Genome Sciences on Thursday said that bolstered R&D to develop new drugs together with shriveled revenue brought on by the end of the Human Gene Consortium caused net losses to widen in the fourth quarter.
Revenue for the period ended Dec. 31 plummeted to $642,000 from $5.3 million one year because the exclusivity of the genetic information it once licensed expired along with the Consortium, giving customers the green light to hunt for the data elsewhere.

R&D in the quarter shot up to $40.3 million compared with $26.7 in the year-ago period as the fledgling drug-development firm ramped up its effort to develop a product. This helped to drive up net loss to $55.2 million, or $.43 a share, compared with a net loss of $6 million, or a nickel a share, in the fourth quarter of 2000.


As of Dec. 31, HGS had about $1.7 billion in cash.

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.